<< Back to News

New FDA Approval for XGEVA®

On January 5, 2018, the U.S. Food and Drug Administration updated the U.S. Prescribing Information for XGEVA® (denosumab) to include patients with multiple myeloma*.  The new indication states:

XGEVA® is a RANK ligand (RANKL) inhibitor indicated for:

  • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors 

Please click here for current full Prescribing Information.